Rigel Announces Closing of Licensing Agreement for VEPPANU™ (vepdegestrant)
Rigel Pharmaceuticals closed the exclusive global licensing agreement with Arvinas and Pfizer for VEPPANU (vepdegestrant) following the expiration of the HSR waiting period. Rigel remitted the $70 million upfront payment to its partners and expects to make the therapy commercially available in August.
Key figures
- Launch timing
- August
- Upfront payment usd
- 70000000
AI analysis
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.